Ventyx Biosciences Inc (VTYX)

$2.30 0.00 (N/A)
Market Cap 164.01M
Revenue (ttm) 0.00
Net Income (ttm) -135.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 545,195
Avg Vol 809,408
Day's Range N/A - N/A
Shares Out 71.31M
Stochastic %K 0%
Beta 0.95
Analysts Strong Sell
Price Target $11.50

Company Profile

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like recept...

Industry: Biotechnology
Sector: Healthcare
Phone: 760 593 4832
Address:
12790 El Camino Real, Suite 200, San Diego, United States
BinaryLogic
BinaryLogic Sep. 15 at 9:50 AM
$VTYX There are certainly no guarantees in small bio-pharma; however, here (below) is part of the Bullish thesis (IMO) underpinning the Company, and the potential upside intermediate term. Review the financial position of the Company, the diversification of its pipeline, its valuation and multiple catalysts over the next 6-12mos, and you should see multiplier upside from current levels.
0 · Reply
Zobzork
Zobzork Sep. 14 at 4:37 PM
$VTYX 4$ before EOY?
0 · Reply
Timah73
Timah73 Sep. 10 at 8:09 PM
$VTYX A worthless stock that has burned millions of investors’ money and keeps falling. If it had real potential, it wouldn’t have dropped from $42 in the first place. They pumped it up to $9 using the obesity narrative for a second scam. Nothing but deception and manipulation
0 · Reply
Theflash88
Theflash88 Sep. 7 at 10:45 PM
$VTYX Ok naysayers: Look at the 3 month and 6 month charts.. We need patience..
0 · Reply
Theflash88
Theflash88 Sep. 7 at 10:44 PM
$VTYX Yes.. I called the company.. $8.50 a share..
1 · Reply
Dr_Monkeybreath
Dr_Monkeybreath Sep. 5 at 9:12 PM
remember when $VTYX dipped under $1.00? i sure do! 👀 $GTBP for a similar move.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 5:39 AM
$VTYX Great piece that accurately captures VTYX's current position. So if you want to refresh your understanding of VTYX or learn about VTYX for the first time, this is essential reading. https://beyondspx.com/quote/VTYX/ventyx-biosciences-unlocking-oral-therapy-s-potential-in-neuroinflammation-and-autoimmunity-nasdaq-vtyx#analysis
0 · Reply
Bionco
Bionco Sep. 3 at 5:48 PM
$CTMX my three babies, $ACRS, $VTYX and $CTMX, all are and will be doing well in the long run!
1 · Reply
Elevate1
Elevate1 Sep. 2 at 1:04 PM
$VTYX This mgmt has been closed mouth unless they have results. The fact they are doing three major healthcare conference starting this Friday and into next week tells me they have a great feel for positive results. They will hint at the positive results by being very confident. The fact they are even coming already tells you this. The Wegovy results about cardiovascular disease being better than LLY’s Mounjaro by a decent amount. This is great new if like I believe their combo pill worked well. Expect a big month here!
0 · Reply
Diverstj981
Diverstj981 Aug. 29 at 4:06 PM
$VTYX Slow bleed 🫣😮‍💨
0 · Reply
Latest News on VTYX
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Aug 27, 2025, 7:02 AM EDT - 19 days ago

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Aug 7, 2025, 4:05 PM EDT - 5 weeks ago

Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

Jun 17, 2025, 7:00 AM EDT - 3 months ago

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson's Disease

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 3 months ago

Ventyx Biosciences to Participate in the Jefferies Global Healthcare Conference

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

May 8, 2025, 4:01 PM EDT - 4 months ago

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Apr 1, 2025, 7:00 AM EDT - 5 months ago

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Feb 27, 2025, 4:05 PM EST - 7 months ago

Ventyx Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Corporate Progress

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Feb 18, 2025, 8:00 AM EST - 7 months ago

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn's Disease at ECCO 2025

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 5, 2025, 8:00 AM EST - 7 months ago

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Jan 14, 2025, 8:00 AM EST - 8 months ago

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Nov 4, 2024, 10:32 AM EST - 11 months ago

Ventyx Biosciences: Ready To Escape "The Crash Cycle"

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences

Sep 23, 2024, 11:13 AM EDT - 1 year ago

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences

SNY

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Sep 6, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson's Disease

Ventyx Biosciences Announces Departure of Chief Financial Officer

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Departure of Chief Financial Officer

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Aug 28, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

Dow Edges Lower; Ventyx Biosciences Shares Plummet

Jul 29, 2024, 2:31 PM EDT - 1 year ago

Dow Edges Lower; Ventyx Biosciences Shares Plummet

Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further

Jul 29, 2024, 11:03 AM EDT - 1 year ago

Ventyx Biosciences' Inflammatory Bowel Disease Candidate Flunks In Mid-Stage Study, Company Looks For Partner To Pursue It Further

VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details

Jun 24, 2024, 6:00 AM EDT - 1 year ago

VENTYX INVESTOR UPDATE: Ventyx's (Nasdaq:VTYX) Board is Being Investigated for Insider Trading, Long-term Investors Are Urged to Contact the Firm for Details

VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details

Jun 21, 2024, 4:15 PM EDT - 1 year ago

VENTYX INVESTOR NOTICE: Ventyx's (NASDAQ:VTYX) Board is Being Investigated for Insider Trading Allegations, Long-term Investors Are Urged to Contact the Firm for Details

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

Jun 20, 2024, 7:20 AM EDT - 1 year ago

VENTYX INVESTOR REMINDER: Ventyx (Nasdaq:VTYX) Shareholders are Urged to Contact BFA Law about its Review of the Board's Insider Trading Scheme

VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses

Jun 19, 2024, 4:20 PM EDT - 1 year ago

VENTYX INVESTIGATION REMINDER: Ventyx (Nasdaq:VTYX) Investors are Urged to Contact BFA Law about Inquiry into the Board for its Insider Trading Scheme and Avoiding Losses

VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses

Jun 18, 2024, 3:42 PM EDT - 1 year ago

VENTYX INSIDER TRADING INQUIRY: Ventyx (VTYX) Shareholders are Urged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Losses

VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 17, 2024, 6:32 AM EDT - 1 year ago

VENTYX NOTIFICATION: Ventyx (VTYX) Shareholders are Encouraged to Contact BFA Law about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

Jun 13, 2024, 4:06 PM EDT - 1 year ago

BFA Law Notice: Ventyx (Nasdaq: VTYX) Shareholders are Encouraged to Contact the Firm about Investigation into the Board for Insider Trading Scheme and Avoiding Substantial Losses

VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm

Jun 13, 2024, 7:13 AM EDT - 1 year ago

VENTYX REMINDER: BFA Law is Investigating Ventyx (Nasdaq: VTYX) Directors for Insider Trading Scheme and Avoiding Substantial Losses, Shareholders are Urged to Contact the Firm

STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading

Jun 12, 2024, 4:04 PM EDT - 1 year ago

STOCK DROP NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Investors are Encouraged to Contact BFA Law about the Investigation into the Company's Board for Insider Trading

VENTYX STOCK NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors

Jun 11, 2024, 3:37 PM EDT - 1 year ago

VENTYX STOCK NOTICE: Ventyx (Nasdaq:VTYX) Stock Drops 20%, Shareholders are Reminded to Contact BFA Law about the Investigation into the Company's Board of Directors

VENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's Board

Jun 11, 2024, 6:41 AM EDT - 1 year ago

VENTYX INVESTIGATION ANNOUNCEMENT: Ventyx (Nasdaq: VTYX) Stock Drops 20%, Investors are Urged to Contact BFA Law about the Investigation into the Company's Board

VENTYX NEWS NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Urged to Contact BFA Law about the Investigation into the Company's Board of Directors

Jun 8, 2024, 5:24 AM EDT - 1 year ago

VENTYX NEWS NOTICE: Ventyx (Nasdaq: VTYX) Shareholders are Urged to Contact BFA Law about the Investigation into the Company's Board of Directors

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

Jun 5, 2024, 4:01 PM EDT - 1 year ago

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

May 16, 2024, 8:00 AM EDT - 1 year ago

Ventyx Biosciences Announces Appointment of Matthew Moore as Chief Operating Officer

Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript

May 11, 2024, 1:58 PM EDT - 1 year ago

Ventyx Biosciences, Inc. (VTYX) Q1 2024 Earnings Call Transcript

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

May 2, 2024, 4:05 PM EDT - 1 year ago

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

Apr 30, 2024, 8:00 AM EDT - 1 year ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

Apr 28, 2024, 7:00 PM EDT - 1 year ago

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses to Contact the Firm

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm

Apr 28, 2024, 1:00 PM EDT - 1 year ago

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Ventyx Biosciences, Inc. with Losses of $100,000 to Contact the Firm

BinaryLogic
BinaryLogic Sep. 15 at 9:50 AM
$VTYX There are certainly no guarantees in small bio-pharma; however, here (below) is part of the Bullish thesis (IMO) underpinning the Company, and the potential upside intermediate term. Review the financial position of the Company, the diversification of its pipeline, its valuation and multiple catalysts over the next 6-12mos, and you should see multiplier upside from current levels.
0 · Reply
Zobzork
Zobzork Sep. 14 at 4:37 PM
$VTYX 4$ before EOY?
0 · Reply
Timah73
Timah73 Sep. 10 at 8:09 PM
$VTYX A worthless stock that has burned millions of investors’ money and keeps falling. If it had real potential, it wouldn’t have dropped from $42 in the first place. They pumped it up to $9 using the obesity narrative for a second scam. Nothing but deception and manipulation
0 · Reply
Theflash88
Theflash88 Sep. 7 at 10:45 PM
$VTYX Ok naysayers: Look at the 3 month and 6 month charts.. We need patience..
0 · Reply
Theflash88
Theflash88 Sep. 7 at 10:44 PM
$VTYX Yes.. I called the company.. $8.50 a share..
1 · Reply
Dr_Monkeybreath
Dr_Monkeybreath Sep. 5 at 9:12 PM
remember when $VTYX dipped under $1.00? i sure do! 👀 $GTBP for a similar move.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 4 at 5:39 AM
$VTYX Great piece that accurately captures VTYX's current position. So if you want to refresh your understanding of VTYX or learn about VTYX for the first time, this is essential reading. https://beyondspx.com/quote/VTYX/ventyx-biosciences-unlocking-oral-therapy-s-potential-in-neuroinflammation-and-autoimmunity-nasdaq-vtyx#analysis
0 · Reply
Bionco
Bionco Sep. 3 at 5:48 PM
$CTMX my three babies, $ACRS, $VTYX and $CTMX, all are and will be doing well in the long run!
1 · Reply
Elevate1
Elevate1 Sep. 2 at 1:04 PM
$VTYX This mgmt has been closed mouth unless they have results. The fact they are doing three major healthcare conference starting this Friday and into next week tells me they have a great feel for positive results. They will hint at the positive results by being very confident. The fact they are even coming already tells you this. The Wegovy results about cardiovascular disease being better than LLY’s Mounjaro by a decent amount. This is great new if like I believe their combo pill worked well. Expect a big month here!
0 · Reply
Diverstj981
Diverstj981 Aug. 29 at 4:06 PM
$VTYX Slow bleed 🫣😮‍💨
0 · Reply
LifeisaMeme
LifeisaMeme Aug. 27 at 6:15 PM
$VTYX Anyone know what the buyout price will be ?
0 · Reply
LifeisaMeme
LifeisaMeme Aug. 26 at 4:39 PM
$VTYX go to 4 dollars so I can sell loser
0 · Reply
Elevate1
Elevate1 Aug. 25 at 8:03 AM
$VTYX
0 · Reply
LifeisaMeme
LifeisaMeme Aug. 22 at 2:07 PM
$VTYX OMG 12 CENTS LMAO
0 · Reply
mf3rs
mf3rs Aug. 20 at 3:15 PM
$VTYX Unless a buyout offer is announced in the meantime. This is probably just going to bounce around until the 4th qtr .
0 · Reply
Quantum_nomics
Quantum_nomics Aug. 19 at 7:01 PM
$VTYX I mean, NASDAQ is down today....but $VKTX #2 trending If there is selling in VTYX It does not make any sense at all And would be a buying op DYOR (I have not done so yet Captain Obvious signing off) 📴
0 · Reply
Elevate1
Elevate1 Aug. 19 at 5:51 PM
$VTYX I believe today’s sell off is either a confusion with Viking Therapeutics symbol! Or the fact they failed due to side effects scared people about this drug! The fact that an etf sold means dumb money sold.
0 · Reply
mf3rs
mf3rs Aug. 19 at 12:50 PM
$VTYX viking dumping today apparently their weight loss pill not tolerable
0 · Reply
Elevate1
Elevate1 Aug. 19 at 12:49 PM
$VTYX it does amaze me that Point 72 doubles its position to 8.2% and the stock still below cash/ shr. Obviously he believes he knows something! I am long
1 · Reply
BinaryLogic
BinaryLogic Aug. 19 at 9:26 AM
$VTYX [Again]
0 · Reply
Sheriff87
Sheriff87 Aug. 18 at 4:35 PM
$VTYX wich way will it go 🤔
0 · Reply
Gemini367
Gemini367 Aug. 15 at 6:01 PM
$TPST chart looking good. Upcoming news catalyst? $VTYX $VKTX still buyout potential.
0 · Reply